Literature DB >> 2157808

Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus.

P Coulon1, V Deutsch, F Lafay, C Martinet-Edelist, F Wyers, R C Herman, A Flamand.   

Abstract

TsO82, a spontaneous temperature-sensitive (ts) mutant of vesicular stomatitis virus (VSV) isolated in chick embryo fibroblasts (CEFs), complements the five prototype ts mutants of the virus. The data presented here indicate that the defect in tsO82 is localized in the M gene. The mutation changed a methionine to an arginine at position 51 of the M protein. Only true revertants could be isolated, and their frequency was low, perhaps due to the type of substitution required to return to the wild-type phenotype. TsO82 does not exhibit hypertranscription, in contrast to the data reported for all of the other ts mutants affected in the M protein. Moreover, tsO82 is conditionally ts, since it grows normally in BHK-21 cells at all temperatures. It exhibits no c.p.e. at the non-permissive temperature in CEFs. Our data argue for multiple functions of the M protein of VSV, the domain affected by the tsO82 mutation possibly being implicated both in the shut-off of cellular RNA synthesis, and for the recognition of a cellular factor required for efficient viral RNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157808     DOI: 10.1099/0022-1317-71-4-991

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  26 in total

Review 1.  Cytopathogenesis and inhibition of host gene expression by RNA viruses.

Authors:  D S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

2.  Infectious hematopoietic necrosis virus matrix protein inhibits host-directed gene expression and induces morphological changes of apoptosis in cell cultures.

Authors:  P P Chiou; C H Kim; P Ormonde; J A Leong
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus.

Authors:  S A Kopecky; M C Willingham; D S Lyles
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release.

Authors:  H R Jayakar; K G Murti; M A Whitt
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

Review 6.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Authors:  Eric Hastie; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2012-10-10       Impact factor: 3.891

7.  Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1.

Authors:  John H Connor; Douglas S Lyles
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells.

Authors:  Guido Wollmann; Vitaliy Rogulin; Ian Simon; John K Rose; Anthony N van den Pol
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

Authors:  Megan Moerdyk-Schauwecker; Nirav R Shah; Andrea M Murphy; Eric Hastie; Pinku Mukherjee; Valery Z Grdzelishvili
Journal:  Virology       Date:  2012-12-14       Impact factor: 3.616

10.  Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology.

Authors:  Himangi R Jayakar; Michael A Whitt
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.